尽管丢失了Q4收入,但DexCom的股票获得了投资者的青睐,价值达到31.07B美元。 Despite missing Q4 earnings, DexCom's stock gained investor favor, reaching a $31.07B valuation.

DexCom是一家医疗设备公司,它看到其股票对Ethos金融集团LLC和Charles Schwab投资管理公司等投资者更具吸引力,这些投资者增加了其股份。 DexCom, a medical device company, saw its stock become more attractive to investors like Ethos Financial Group LLC and Charles Schwab Investment Management Inc., who increased their holdings. 尽管缺少Q4收入估计数,但DexCom的股票获得“移动买家”评级,分析员提供99.82美元目标价格。 Despite missing Q4 earnings estimates, DexCom's stock received a "Moderate Buy" rating with a $99.82 target price from analysts. 机构投资者现在拥有该公司股票的97.75%,价值31.07亿美元。 Institutional investors now own 97.75% of the company's stock, valued at $31.07 billion.